Scholarlink

Background <p>Acute myeloid leukemia is a hematological malignancy characterized by acquired genomic aberrations. Mutations in the <i>FMS-like tyrosine kinase 3</i> gene cause constitutive activation of downstream signaling pathways, thereby driving disease progression and conferring a poor prognosis. Gilteritinib, a tyrosine kinase inhibitor, is a promising treatment for <i>FMS-like tyrosine kinase 3</i>-mutated acute myeloid leukemia. However, gilteritinib resistance remains a significant concern, and its underlying mechanisms are not yet understood.</p> Case presentation <p>A 65-year-old Japanese male patient who was receiving regular hemodialysis developed pancytopenia in 2017. He required recurrent red blood cell transfusions due to anemia&#xa0;in 2018. In 2019, he was diagnosed with myelodysplastic syndrome with excess blasts. We administered three courses of azacitidine but ceased it due to severe cytopenia. His disease had transformed to acute myeloid leukemia. The fourth course of azacitidine was administered, but it was ineffective. Since a tyrosine kinase domain mutation in <i>FMS-like tyrosine kinase 3</i> was detected in the acute myeloid leukemia cells, we administered gilteritinib at a dose of 120 mg. Although the treatment initially showed efficacy, the disease progressed, and he died 7 days after the initiation of gilteritinib. To assess the epigenetic changes in acute myeloid leukemia during the treatment with gilteritinb, we performed the assay for transposase-accessible chromatin with sequencing using the leukemia cells obtained from the patient before and after gilteritinib treatment. After the treatment, greater than fivefold changed assay for transposase-accessible chromatin peaks were detected in 137 (upregulated) and 105 (downregulated) regions. Among them, half of the regions were located in the intergenic regions. A Gene Ontology analysis of affected genes listed the mitogen‑activated protein kinase pathway, which is potentiated by the <i>FMS-like tyrosine kinase 3</i> genetic mutations in leukemia cells. No significant changes were noted at the <i>FMS-like tyrosine kinase 3</i> locus. On the gene locus of <i>PPP2R2B,</i> a known cancer-associated gene, the peaks were decreased, suggesting reduced chromatin accessibility. Conversely, upregulation peaks were observed on the gene locus and adjacent noncoding region of <i>PDGFD</i> that is associated with the progression of various types of cancer including acute myeloid leukemia.</p> Conclusions <p>Our study demonstrated the epigenetic changes in acute myeloid leukemia cells that may be associated with gilteritinib resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Assessment of chromatin remodeling of acute myeloid leukemia cells treated with gilteritinib: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月3日

查看全文
  • Jinichi Mori,
  • Takahiro Sawada,
  • Koki Nojiri,
  • Yoshiaki Kanemoto,
  • Tadashi Okada,
  • Tomohiro Kurokawa,
  • Shigeaki Kato

摘要

Background

Acute myeloid leukemia is a hematological malignancy characterized by acquired genomic aberrations. Mutations in the FMS-like tyrosine kinase 3 gene cause constitutive activation of downstream signaling pathways, thereby driving disease progression and conferring a poor prognosis. Gilteritinib, a tyrosine kinase inhibitor, is a promising treatment for FMS-like tyrosine kinase 3-mutated acute myeloid leukemia. However, gilteritinib resistance remains a significant concern, and its underlying mechanisms are not yet understood.

Case presentation

A 65-year-old Japanese male patient who was receiving regular hemodialysis developed pancytopenia in 2017. He required recurrent red blood cell transfusions due to anemia in 2018. In 2019, he was diagnosed with myelodysplastic syndrome with excess blasts. We administered three courses of azacitidine but ceased it due to severe cytopenia. His disease had transformed to acute myeloid leukemia. The fourth course of azacitidine was administered, but it was ineffective. Since a tyrosine kinase domain mutation in FMS-like tyrosine kinase 3 was detected in the acute myeloid leukemia cells, we administered gilteritinib at a dose of 120 mg. Although the treatment initially showed efficacy, the disease progressed, and he died 7 days after the initiation of gilteritinib. To assess the epigenetic changes in acute myeloid leukemia during the treatment with gilteritinb, we performed the assay for transposase-accessible chromatin with sequencing using the leukemia cells obtained from the patient before and after gilteritinib treatment. After the treatment, greater than fivefold changed assay for transposase-accessible chromatin peaks were detected in 137 (upregulated) and 105 (downregulated) regions. Among them, half of the regions were located in the intergenic regions. A Gene Ontology analysis of affected genes listed the mitogen‑activated protein kinase pathway, which is potentiated by the FMS-like tyrosine kinase 3 genetic mutations in leukemia cells. No significant changes were noted at the FMS-like tyrosine kinase 3 locus. On the gene locus of PPP2R2B, a known cancer-associated gene, the peaks were decreased, suggesting reduced chromatin accessibility. Conversely, upregulation peaks were observed on the gene locus and adjacent noncoding region of PDGFD that is associated with the progression of various types of cancer including acute myeloid leukemia.

Conclusions

Our study demonstrated the epigenetic changes in acute myeloid leukemia cells that may be associated with gilteritinib resistance.